Inovio Pharmaceuticals Inc
GBM
Company Profile
Business description
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Contact
660 West Germantown Pike
Suite 110
Plymouth MeetingPA19462
USAT: +1 267 440-4200
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
134
Stocks News & Analysis
stocks
Meta earnings: Strong end to 2025 as AI monetization begins to show
Investors please with latest results.
stocks
Why doesn’t the market like the earnings from this US tech giant?
Good quarter with AI demand ramping.
stocks
Our Tesla fair value increases meaningfully
Progress on Robotaxi and Optimus shows real world AI growth.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,164.80 | 94.40 | -1.02% |
| CAC 40 | 8,125.80 | 54.44 | 0.67% |
| DAX 40 | 24,499.72 | 190.26 | 0.78% |
| Dow JONES (US) | 49,071.56 | 55.96 | 0.11% |
| FTSE 100 | 10,214.45 | 42.69 | 0.42% |
| HKSE | 27,387.11 | 580.98 | -2.08% |
| NASDAQ | 23,685.12 | 172.33 | -0.72% |
| Nikkei 225 | 53,322.85 | 52.75 | -0.10% |
| NZX 50 Index | 13,423.18 | 74.57 | 0.56% |
| S&P 500 | 6,969.01 | 9.02 | -0.13% |
| S&P/ASX 200 | 8,869.10 | 86.00 | -0.96% |
| SSE Composite Index | 4,117.95 | 40.04 | -0.96% |